Nebilet (ingredient: nebivolol hydrochloride), a third-generation beta-blocker for hypertension developed by Menarini, proved efficacy in Korean hypertensive patients in the sub-group analysis of the real-world BENEFIT study, the company said.
Menarini presented the sub-group analysis results in a poster session during Hypertension 2021, a joint online conference by the International Society of Hypertension (ISH) and the European Society of Hypertension (ESH) held on Sunday to Wednesday.
Earlier, the company had released the outcome of the BENEFIT study that administered Nebilet to 3,250 adult patients with hypertension at 66 local hospitals from July 2015 to March 2017 and observed the therapeutic effect for 24 weeks.
The latest data is the analysis of various sub-groups in the BENEFIT trial.
Professor Shin Jin-ho of the Cardiology Department of Hanyang University Medical Center presented the analysis results, explaining the effect of current heart rate on nebivolol’s efficacy in hypertensive patients.
“According to the analysis results considering age, sex, obesity, diabetes, and cardiovascular disease in the BENEFIT study, the nebivolol effect was greater in patients who had higher heart rates at the beginning of the study,” Shin said. The results are consistent with the ESH’s 2018 guidelines that recommended a beta-blocker for patients with a high heart rate.
Professor Lee Jong-young of the Cardiology Division of Kangbuk Samsung Hospital presented the efficacy and safety of nebivolol in managing hypertension with coronary artery disease (CAD). “The analysis showed that nebivolol could be a useful option to treat hypertension complicated by CAD,” Lee said.
Park Hye-young, general manager of Menarini Korea, said the company wanted to share the results of the BENEFIT study, which supported ESC and ESH’s 2018 hypertension guidelines, which called a beta-blocker “effective.”
“We will continue to provide useful treatment options for Korean hypertensive patients by confirming the effectiveness and safety of Nebilet through various studies in the future,” she said.
Menarini is selling Nebilet in 78 countries, including the U.S. and Germany. The drug arrived in Korea in June 2009. Menarini Korea began selling the low-dose product Nebilet M in December 2020, providing treatment options for local hypertensive patients with various characteristics.